RESEARCH ON PHARMACOKINETICS OF NEW FORMULIZATION OF DIINDOLYLMETHANE AT PATIENTS WITH HYPERPLASIA OF ENDOMETRIUM
Abstract
The pharmacokinetics of new formulization Cineton on the basis of active ingredient 33,3’-diindolylmethane (DIM) containing pluronic is studied, 5 patients with hyperplasia have endometrium without atypia. DIM concentration in blood plasma was determined by method of a highly effective liquid chromatography with UF-detecting after single oral administration of preparation in a dose of 300 mg of DIM. The average AUC size made 343,9 ± 112,9 ng h/ml, average maximum concentration (Cmax) of DIM in blood plasma - 121,5 ± 38,7 ng/ml, average time of achievement of Cmax - 2,2 ± 0,45 h. It is established that the DIM substance is defined in blood plasma of patients during 10 hours after single introduction of preparation, calculated average time of deduction of preparation in systemic blood flow (MRT0inf) made 4,4 ± 1,35 h. The period of semi-removal (T1/2) made 1,9 ± 1,6 h. The received results confirmed high bioavailability of Cineton preparation.
About the Authors
V. M. Drukh
FSAEE HE «Peoples’ Friendship University of Russia»
Russian Federation
Russian Federation
M. A. Paltsev
FSBE «Russian Academy of Science»
Russian Federation
Russian Federation
I. N. Kuznetsov
SBEI HPE «Moscow state medical stomatological university n. a. A. I. Evdokimov» of Ministry of Health
Russian Federation
Russian Federation
E. A. Andrianova
JSC «IlmixGroup»
Russian Federation
Russian Federation
P. M. Baranovsky
SRC «The Kurchatov Institute»
Russian Federation
Russian Federation
References
1. Global cancer statistics, 2012 / L. A. Torre [et al.] // CA Cancer J. Clin. -2015. - Vol. 65. - P. 87-108.
2. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide : IARC CancerBase No. 11 [Internet] / J. Ferlay [et al.] // Lyon, France : International Agency for Research on Cancer. - 2013. - Access mode : (http://globocan.iarc.fr, accessed on day/month/year). - Access date : 01.08.2015.
3. Holland C. The modern management of endometrial cancer / C. Holland, H. Kitchener // Oncol. Rev.- 2007. - Vol. 1. - P. 103-119.
4. Qvigstad E. Surgical Treatment of Endometrial Cancer and Atypical Hyperplasia : A Trend Shift from Laparotomy to Laparoscopy/ E. Qvigstad, M. Lieng // Obstet. Gynecol. Int. - 2011. - DOI: 10.1155/2011/829425.
5. Press J. Z. Controversies in the Treatment of Early Stage Endometrial Carcinoma / J. Z. Press, W. H. Gotlieb // Obstet. Gynecol. Int. - 2012. - DOI:10.1155/2012/578490.
6. Coexisting endometrial cancer in patients with a preoperative diagnosis of atypical endometrial hyperplasia / T. Bilgin [et al.] // Obstet. Gynaecol. Res. - 2004. - Vol. 30. - P. 205-9.
7. Molecular pathology of endometrial hyperplasia and carcinoma / X. Mattias-Guiu [et al.] // Hum. Pathol. - 2001. - Vol. 32. - P. 569-77.
8. The behavior of endometrial hyperplasia : a prospective study. Endometrial Hyperplasia Study Group / N. Terakawa [et al.] // J. Obstet. Gynaecol. Res. - 1997. - Vol. 23. - P. 223-30.
9. Molecular analysis of endometrial tumorigenesis : importance of complex hyperplasia regardless of atypia / T. T. Nieminen [et al.] // Clin. Cancer Res. - 2009. - Vol. 15. - P. 5772-83.
10. Rogan E. G. The natural chemopreventive compound indole-3-carbinol: state of the science / E. G. Rogan // In Vivo. - 2006. - Vol. 20. - P. 221-8.
11. Attenuation of multi-targeted proliferation-linked signaling by 3,3′-diindolylmethane (DIM) : from bench to clinic / S. Banerjee [et al.] // Mutat. Res. - 2011. - Vol. 728. - P. 47-66.
12. Leong H. Cytostatic effects of 3,3’-diindolylmethane in human endometrial cancer cells result from an estrogen receptor-mediated increase in transforming growth factor-alpha expression / H. Leong, G. L. Firestone, L. F. Bjeldanes // Carcinogenesis. -2001. - Vol. 22. - P. 1809-17.
13. Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane / I. Chen [et al.] // Carcinogenesis. - 1998. - Vol. 19. - P. 1631-39.
14. Estrogen and progesterone receptors and cyclooxygenase-2 expression in endometrial cancer, endometrial hyperplasia, and normal endometrium / F. J. Orejuela [et al.] // Gynecol. Oncol. - 2005. - Vol. 97. - P. 483-8.
15. Effect of 3,3′-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer / K. M. Dalessandri [et al.] // Nutr. Cancer. - 2004. - Vol. 50. - P. 161-7.
16. Lord R. S. Estrogen metabolism and the diet-cancer connection : rationale for assessing the ratio of urinary hydroxylated estrogen metabolites / R. S. Lord, B. Bongiovanni, J. A. Bralley // Altern. Med. Rev. - 2002. - Vol. 7. - P. 112-29.
17. ,3’-Diindolylmethane inhibits angiogenesis and the growth of transplantable human breast carcinoma in athymic mice / X. Chang [et al.] // Carcinogenesis. - 2005. - Vol. 26. - P. 771-8.
18. Kojima T. Chemoprevention of Spontaneous Endometrial Cancer in Female Donryku Rats by Dietary Indole-3-carbinol / T. Kojima, T. Tanaka, H. Mori // Cancer Res. - 1994. - Vol. 54. - P. 1446-9.
19. ,3’-Diindolylmethane (DIM) induces a G1 cell cycle arrest in human breast cancer cells that is accompanied by Sp1-mediated activation of p21WAF1/CIP1 expression / C. Hong [et al.] // Carcinogenesis. - 2002. - Vol. 23. - P. 1297-1305.
20. Hong C. Bcl-2 family-mediated apoptotic effects of 3,3’-diindolylmethane (DIM) in human breast cancer cells / C. Hong, G. L. Firestone, L. F. Bjeldanes // Biochem. Pharmacol. - 2002. - Vol. 63. - P. 1085-97.
21. ,3’-diindolylmethane attenuates colonic inflammation and tumorigenesis in mice / Y. H. Kim [et al.] // Inflamm. Bowel Dis. - 2009. - Vol. 15. - P. 1164-73.
22. Antiangiogenic effects of indole-3-carbinol and 3,3’-diindolylmethane are associated with their differential regulation of ERK1/2 and Akt in tube-forming HUVEC / K. Kunimasa [et al.] // J. Nutr. - 2010. - Vol. 140. - P. 1-6.
23. Epigenetic modifications of Nrf2 by 3,3’-diindolylmethane in vitro in TRAMP C1 cell line and in vivo TRAMP prostate tumors / T. Y. Wu [et al.] // AAPS J. - 2013. - Vol. 15. - P. 864-74.
24. Diindolylmethane (DIM) selectively inhibits cancer stem cells / A. Semov [et al.] // Biochem. Biophys. Res. Commun. - 2012. - Vol. 424. - P. 45-51.
25. Single-dose and multiple-dose administration of indole-3-carbinol to women : pharmacokinetics based on 3,3’-diindolylmethane/ G. A. Reed [et al.] // Cancer Epidemiol. Biomarkers Prev. - 2006. - Vol. 15. - P. 2477-81.
26. Изучение эффективности новой фармацевтической композиции дииндолилметана в отношении подавления ксенографтов опухолей эндометрия [Электронный ресурс] / В. И. Киселев [и др.] // Медицина и образование в Сибири : сетевое научное издание. - 2014. - № 5. - Режим доступа : (http://ngmu.ru/cozo/mos/article/text_full.php?id=1550). - Дата обращения : 01.08.2015.
27. Diindolylmethane-based drug for the treatment of hyperplastic and inflammatory diseases. WO 2011/136691 A1. V.I. Kiselev.
28. Single-dose pharmacokinetics and tolerability of absorption-enhanced 3,3’-diindolylmethane in healthy subjects / G. A. Reed [et al.] // Cancer Epidemiol. Biomarkers Prev. - 2008. - Vol. 17. - P. 2619-24.
29. Pharmacokinetic evaluation and in vitro-in vivo correlation (IVIVC) of novel methylene-substituted 3,3′ diindolylmethane (DIM) / A. R. Patel [et al.] // Eur. J. Pharm. Sci. - 2012. - Vol. 46. - P. 8-16.
30. Comparative preclinical pharmacokinetics study of 3,3’-diindolylmethane formulations : is personalized treatment and targeted chemoprevention in the horizon? / M. Paltsev [et al.] // EPMA J. - 2013. - N 4. - Access mode : (http://www.epmajournal.com/content/4/1/25). - Access date : 01.08.2015.
Review
For citations:
Drukh V.M., Paltsev M.A., Kuznetsov I.N., Andrianova E.A., Baranovsky P.M. RESEARCH ON PHARMACOKINETICS OF NEW FORMULIZATION OF DIINDOLYLMETHANE AT PATIENTS WITH HYPERPLASIA OF ENDOMETRIUM. Journal of Siberian Medical Sciences. 2015;(5):48.
Views:
258
Email this article 